AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00544882
Drug: Mircette®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
Trial: NCT00544882
Drug: Kariva®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
Trial: NCT02359617
Drug: insulin delivery
RxNorm normalized name: Insulin Delivery Needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.
Trial: NCT01231490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01231490
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT04374136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via intravenous (IV) infusion
Trial: NCT03318471
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes
Trial: NCT00479258
Drug: Inhaled insulin (Exubera)
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin with dose adjusted according to premeal blood glucose
Trial: NCT02985593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03480776
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 81 mg PO daily or 325 mg PO daily
Trial: NCT01746017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as capsules
Trial: NCT01746017
Drug: LY2922470
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as capsules
Trial: NCT03422653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV medication delivered three times/week
Trial: NCT01825447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.
Trial: NCT03199547
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The women will be randomized to receive a single dose of Azithromycin or Placebo
Trial: NCT03199547
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The women will be randomized to receive a single dose of Azithromycin or Placebo
Trial: NCT04132622
Drug: Levothyroxine Sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine Sodium Tablets (50 ug, calculated by Levothyroxine Sodium ), produced by Merck KGaA, Darmstadt.
Trial: NCT04132622
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: including steroids, vitamin C, hemodialysis and blood perfusion.
Trial: NCT04037748
Drug: Puran T4®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who received a single oral dose of Puran T4® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
Trial: NCT04037748
Drug: Eutirox®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who received a single oral dose of Eutirox® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
Trial: NCT00871182
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, inhaled
Trial: NCT04998838
Drug: Regular Myanmar treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treated according to normal Myanmar processes for HBV positive patients
Trial: NCT01390766
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00771485
Drug: Marketed Bowel Cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed bowel cleanser
Trial: NCT01215266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 3-21 2x2 800 mg(milligram) daily
Trial: NCT03152981
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
Trial: NCT01856205
Drug: Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.~Placebo group received 0.9% saline intravenous at similar rate.
Trial: NCT01375660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
Trial: NCT03653260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injector, 20 Bar pressure, empty injector
Trial: NCT00162474
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03473249
Drug: Contrast-Enhanced Ultrasound using Lumason
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will undergo a contrast enhanced ultrasound (CEUS) during which a standard greyscale abdominal ultrasound is performed first followed by injection of intravenous contrast with Lumason, and completion of contrast-enhanced ultrasound
Trial: NCT03660020
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy with local anaesthetics only
Trial: NCT00496964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 2 cc placebo containing 0.1cc sodium bicarbonate 8.4% (1meq/cc), 0.9cc normal saline and 1 cc of lidocaine into the vastus lateralis of the study leg followed by 12 weeks of exercise for patellofemoral pain syndrome
Trial: NCT00303784
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
Trial: NCT01091974
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 47 days
Trial: NCT01820364
Drug: LGX818
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
Trial: NCT03451084
Drug: ASLAN003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.
Trial: NCT00966342
Drug: Fluviral 2009/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose given IM .05 mL
Trial: NCT00398580
Drug: Nanomilled testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00909610
Drug: Urso Forte™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urso Forte™ Tablets, 500 mg
Trial: NCT00454259
Drug: Fentanyl/Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra low dose intravenous injection
Trial: NCT02349594
Drug: Omegaven 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration 10% (w/v) fish oil emulsion (Omegaven) for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
Trial: NCT00077363
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03292809
Drug: CyclASol topical ocular, eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A solution in vehicle
Trial: NCT03292809
Drug: Vehicle topical ocular, eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT03013634
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equal volume normal saline substitute for dexmedetomidine
Trial: NCT00857935
Drug: NatrOVA Creme Rinse - 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NatrOVA Creme Rinse, one or two, 10-minute topical treatments (7 days apart)
Trial: NCT02326610
Drug: Human growth hormone,ZOMACTON® (somatropin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose will be 30µg/kg/day. The maximal dose will be 40µg/kg/day. The dose will be adjusted by monitoring the serum IGF-I level. Growth hormone will be delivered by injection.
Trial: NCT01482377
Drug: RO5479599
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).
Trial: NCT02919631
Drug: Placebo oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil
Trial: NCT01702714
Drug: RO5083945
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple ascending doses
Trial: NCT02777268
Drug: Infacort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-particulate granules
Trial: NCT02777268
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet
Trial: NCT01355757
Drug: Single Injection of Local Anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of 20 ml ropivacaine 0.5%
Trial: NCT03089775
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Comparator
Trial: NCT00362934
Drug: fenofibrate / simvastatin
RxNorm normalized name: fenofibrate / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fenofibrate and simvastatin 20 mg and 40 mg
Trial: NCT00471705
Drug: Glucantime®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
Trial: NCT00485771
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000430
Drug: Estrogen/progestin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01196260
Drug: Capecitabine and Oxaliplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine and Oxaliplatin will be under the NSCLC guideline
Trial: NCT03735030
Drug: Human hCG 10'000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 10'000 IU of human hCG will be injected in 24 healthy subject volunteers.
Trial: NCT01826110
Drug: [11C]PIB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 15 mCI \[11C\]PIB IV x1
Trial: NCT03496623
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution
Trial: NCT03065660
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be an oral tablet in the same form as the IMP, and identical in appearance.
Trial: NCT04452474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
Trial: NCT04130802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle eye drops
Trial: NCT01384292
Drug: NKTR-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg oral tablet once daily
Trial: NCT01384292
Drug: NKTR-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral tablet once daily
Trial: NCT01384292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment
Trial: NCT02266433
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study~Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders.
Trial: NCT03987087
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy
Trial: NCT03324360
Drug: Hyperpolarized 13C-Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI with Hyperpolarized 13C-Pyruvate Injection
Trial: NCT03260569
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to this arm will receive inhaled nitric oxide 20 parts per million.
Trial: NCT01469559
Drug: Novolin Toronto insulin
RxNorm normalized name: insulin isophane / insulin, regular, human Injectable Suspension [Novolin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to active drug are provided with 20 IU BID of Novolin Toronto at randomization (week 5). The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast) and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. Dose escalations occur every 2 weeks with the insulin increasing to 40 IU BID at week 7, then 80 IU BID at week 9. The study completes at week 11. The total treatment period is 6 weeks. The insulin is diluted with an amount of normal saline to provide a total volume in the study treatment vial to equal 1.1 milliliters.
Trial: NCT00603616
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo pills to be taken twice daily for a total of 8 weeks
Trial: NCT01022632
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
Trial: NCT03408483
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is currently the standard of care, no local anesthetic will be injected. Pain will be managed with parenteral and oral medication.
Trial: NCT00448019
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/m\^2 IV over 30 minutes daily for 3 days
Trial: NCT00002905
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002905
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00798447
Drug: MLF 541
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
Trial: NCT03086473
Drug: Caffeine Citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention in this study is timing of the initial caffeine dose. In the Caffeine arm, participants will receive Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) within 2 hours of life, and Normal Saline (0.9% NaCl) 1ml/kg IV at 12 hours of life.
Trial: NCT03146000
Drug: meloxicam rectal suppository
RxNorm normalized name: meloxicam Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suppository
Trial: NCT03247920
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotic therapy following local protocol
Trial: NCT00585000
Drug: CP-675,206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.
Trial: NCT03173391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID Oral administration
Trial: NCT01748279
Drug: Lactose tablet
RxNorm normalized name: lactose Oral Tablet
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One lactose tablet taken once a day as add-on treatment to Formoterol therapy
Trial: NCT03962686
Drug: statin Oral Tablet plus PCSK9i
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the third study cohort will receive for statin oral therapy plus 140 mg twice a month PCSK9i therapy via subcutaneous injection before to practice surgical intervention for carotid artery obstruction.
Trial: NCT00239616
Drug: iron sucrose injection USP
RxNorm normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00111280
Drug: TMC125
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03228355
Drug: Levcromakalim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To investigate the role of Levcromakalim on cerebral hemodynamic in migraine patients
Trial: NCT05040828
Drug: No oral drug therapy throughout the pollen period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Trial: NCT03741114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients received 100 ml saline just before skin incision
Trial: NCT01053390
Drug: epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01147744
Drug: GSK2190915 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 100mg (1 x 100mg) once daily in the morning
Trial: NCT01147744
Drug: GSK2190915 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 10mg (1 x 10mg) once daily in the morning
Trial: NCT01147744
Drug: GSK2190915 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning
Trial: NCT01147744
Drug: GSK2190915 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 30mg (1 x 30mg) once daily in the morning
Trial: NCT01147744
Drug: Placebo GSK2190915 one tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, one tablet once daily in the morning
Trial: NCT01314417
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 μg/100 μL monthly injections for the first 3 months, then as needed per the treatment criteria
Trial: NCT04627038
Drug: LY3556050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3556050 Given orally
Trial: NCT04627038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Given orally
Trial: NCT01147744
Drug: Placebo GSK2190915 two tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, two tablets once daily in the morning
Trial: NCT01641900
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
Trial: NCT00199056
Drug: Dexamethasone / Prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00199056
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199056
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02073175
Drug: Motherwell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.
Trial: NCT01585272
Drug: ENA713
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00941174
Drug: 13C5-Calcium-L-Leucovorin
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.